Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603022 | 0.89 | KDM4E (0.46) | SIGMAR1DRD4TMEM97DRD3GRM2 | |
| SCHEMBL605452 | 0.86 | JAK2 (0.46) | SIGMAR1DRD4TMEM97DRD3PDE2A | |
| SCHEMBL606939 | 0.83 | DRD4 (0.45) | SIGMAR1DRD4TMEM97DRD3GRM2 | |
| SCHEMBL613535 | 0.82 | CARM1 (0.49) | OPRM1SIGMAR1DRD4TMEM97DRD3 | |
| SCHEMBL606815 | 0.81 | CARM1 (0.52) | SIGMAR1DRD4TMEM97CARM1PRMT6 | |
| SCHEMBL605916 | 0.81 | JAK2 (0.44) | OPRM1SIGMAR1DRD4TMEM97DRD3 | |
| SCHEMBL5794907 | 0.80 | SLC6A5 (0.45) | SIGMAR1DRD4TMEM97DRD3LMNA | |
| SCHEMBL604137 | 0.80 | SIGMAR1 (0.64) | SIGMAR1DRD4TMEM97DRD3 | |
| SCHEMBL607017 | 0.79 | DRD4 (0.43) | SIGMAR1DRD4TMEM97DRD3CARM1 | |
| SCHEMBL603293 | 0.78 | DRD4 (0.46) | SIGMAR1DRD4TMEM97DRD3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | claimed |
| EP-1651634-A1 | IMIDAZOL DERIVATIVES OF PIPERIDINE AS HISTAMINE ANTAGONISTS | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014579-A1 | IMIDAZOL DERIVATIVES OF PIPERDINE AS HISTAMINE ANTAGONISTS | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185163-A1 | Imidazol derivatives of piperidine as histamine antagonists | HRH2, HRH1, HRH4 | OPRM1 36/4885SIGMAR1 184/4885DRD4 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.